| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2016-04-06 | Allergan (Ireland) | Pfizer (USA - NY) | $160 billion | |
| 2016-04-04 | Nimbus Apollo (USA - MA) | Gilead Sciences (USA - CA) | up to 1.2 billion | Liver diseases - Hepatic diseases - Cancer - Oncology |
| 2016-04-01 | Padlock Therapeutics (USA - MA) | BMS (USA - NY) | up to $ 600 million | |
| 2016-03-31 | Affymetrix (USA - CA) | Thermo Fisher Scientific (USA - MA) | $1.3 billion | Technology - Services |
| 2016-03-31 | Amryt Pharmaceuticals (UK) | Fastnet Equity (UK) | £29.6 million | Rare diseases |
| 2016-03-31 | Advantar Laboratories (USA - CA) | Eurofins Scientific (Luxembourg) | undisclosed | |
| 2016-03-18 | Magnis Therapeutics | Omnis Pharma | undisclosed | Cancer- Oncology
|
| 2016-03-16 | Protein Technologies (USA - AZ) | Gyros (Sweden) | undisclosed | Technology - Services |
| 2016-03-11 | ams Laboratories (Australia) | Eurofins Scientific (Luxembourg) | undisclosed | Analytical services |
| 2016-03-07 | Genable Technologies (Ireland) | Spark Therapeutics (USA - PA) | undisclosed | Gene therapy Ophtalmological diseass |
| 2016-02-29 | DNA Therapeutics (France) | Onxeo (France) | €1.7 million in common shares and milestones including up to €25 million per indication developed and approved | Cancer - Oncology - Rare diseases |
| 2016-02-24 | Sandoz Industrial Products GmbH (Germany), a Novartis subsidiary (Switzerland) | International Chemical Investors (Luxembourg) | undisclosed | Manufacturing Production |
| 2016-02-22 | BMS's HIV R&S portfolio | ViiV Healthcare (UK - USA) | up to $ 1.45 billion and milestone payments | Infectious diseases |
| 2016-02-08 | FSC Holdings (USA - NC) | Flamel Technologies (France) | up to $ 53 million | pediatric drugs |
| 2016-02-03 | Transgene's production asset | ABL Europe, a member of Institut Merieux (France) | ||
| 2016-02-02 | Acerta Pharma (USA - CA, The Netherlands) | AstraZeneca (UK) | $ 4 billion | Cancer- Oncology |
| 2016-01-25 | Q-Biologicals (Belgium) | Amatsigroup (France) | undisclosed | Technology - Services |
| 2016-01-22 | Dyax (USA - MA) | Shire (UK - USA) | $5.9 billion (€5.38 billion) | Rare diseases Genetic diseases |
| 2016-01-20 | Kuros Biosurgery (Switzerland) | Cytos Biotechnology (Switzerland) | Regenerative medicine Allergic diseases Cancer - Oncology |
|
| 2016-01-13 | Sinensis Life Sciences (The Netherlands) | Eurofins Scientific (Luxembourg) | undisclosed | Analytical services |
